IRIS - Res&Arch Institutional Research Information System - Research & Archive

GAETANI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.028
EU - Europa 593
AS - Asia 311
SA - Sud America 5
AF - Africa 4
Totale 1.941
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.027
IE - Irlanda 213
IT - Italia 157
HK - Hong Kong 145
SG - Singapore 87
CN - Cina 61
SE - Svezia 59
FI - Finlandia 28
DE - Germania 22
RU - Federazione Russa 20
CZ - Repubblica Ceca 17
RO - Romania 17
FR - Francia 13
BE - Belgio 12
UA - Ucraina 10
GB - Regno Unito 9
JP - Giappone 5
VN - Vietnam 5
EG - Egitto 4
GR - Grecia 4
NL - Olanda 4
AT - Austria 3
BR - Brasile 3
CO - Colombia 2
IR - Iran 2
PL - Polonia 2
UZ - Uzbekistan 2
CA - Canada 1
CH - Svizzera 1
ES - Italia 1
KR - Corea 1
LB - Libano 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
TW - Taiwan 1
Totale 1.941
Salva come PNG Salva come JPEG
Città #
Chandler 254
Dublin 213
Hong Kong 144
San Mateo 65
Perugia 60
Altamura 59
Singapore 53
Des Moines 42
Lawrence 39
Medford 39
Princeton 39
Andover 38
Ann Arbor 38
Wilmington 34
Ashburn 33
Boardman 31
Beijing 25
Redmond 24
Redwood City 18
Helsinki 16
Los Angeles 16
Falls Church 13
Brno 12
Brussels 12
Timisoara 10
Houston 9
Fairfield 7
Bucharest 6
Lappeenranta 6
Munich 6
Norwalk 6
Saint Petersburg 6
Seattle 6
Dong Ket 5
Rome 5
Tokyo 5
Woodbridge 5
Chicago 4
Milan 4
Amsterdam 3
Giza 3
Moscow 3
Olomouc 3
Bogotá 2
Brixen 2
Cambridge 2
Foligno 2
Jacksonville 2
New York 2
San Paolo di Civitate 2
Turin 2
Vienna 2
Baltimore 1
Bollebygd 1
Böblingen 1
Chiaravalle 1
Curitiba 1
Dearborn 1
Florence 1
Frankfurt am Main 1
Fremont 1
Groningen 1
Hsinchu 1
Izmir 1
Madrid 1
Mogi Guacu 1
Monselice 1
Montreuil 1
Nanjing 1
Napoli 1
Paris 1
Parma 1
Radeberg 1
Secaucus 1
Seoul 1
Shanghai 1
Shibin al Kawm 1
Tappahannock 1
Teresina 1
Tulsa 1
Vancouver 1
Wuhan 1
Totale 1.467
Salva come PNG Salva come JPEG
Nome #
CSF and blood biomarkers for Parkinson's disease 113
Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis 91
Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis 77
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 68
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation 64
Visual pathway involvement in multiple sclerosis: Look straight in the eyes 59
Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis 56
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 56
2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes 54
Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes 50
Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency 49
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation 47
Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis 47
Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature 45
Molecular profiling in Parkinsonian syndromes: CSF biomarkers 44
Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis 43
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica 42
Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers 40
Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain 39
High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline 39
Serum neurofilament light chain as a preclinical marker of neurodegeneration 38
The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. 37
Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease 36
Infliximab monotherapy for neuro-Behçet's disease: a case report 35
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion 35
Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis 35
A blood test for Alzheimer's disease: a step forward 33
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease 32
High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease 32
Synaptic dysfunction in multiple sclerosis: A red thread from inflammation to network disconnection 32
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis 32
Neurofilament light chain as a biomarker in neurological disorders 31
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 31
Finding a way to preserve mitochondria: New pathogenic pathways in experimental multiple sclerosis 30
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 29
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI 29
Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms 29
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction 27
Insights into the pathophysiology of psychiatric symptoms in central nervous system disorders: Implications for early and differential diagnosis 26
Blood biomarkers may distinguish among dementia disorders 25
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 25
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 22
Impact of post-contrast MRI in the definition of active multiple sclerosis 20
Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use 19
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 19
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 19
Clinical correlates of state and trait anxiety in multiple sclerosis 17
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 15
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 12
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 12
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD 11
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 11
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 11
Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents 11
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 10
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 10
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 8
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 8
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 8
SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis 6
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis – a multicentre study 6
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 6
A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis 5
Intrathecal B cell activation and memory impairment in multiple sclerosis 4
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 4
Hippocampal neuroplasticity and inflammation: Relevance for multiple sclerosis 4
Totale 2.060
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.820
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.820
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020115 3 1 0 3 2 2 1 15 7 22 21 38
2020/2021157 3 4 4 1 72 17 7 20 11 5 6 7
2021/2022372 3 46 12 12 25 10 5 91 17 46 61 44
2022/2023843 44 184 15 67 62 102 4 36 294 1 25 9
2023/2024505 24 53 15 11 7 2 95 20 68 25 78 107
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 2.060